|
Abstract:
|
Today physicians and patients alike are confronted with a large amount of information on research, treatments, products, problems, and advisories. This information is available from regulatory bodies such as the US Food and Drug Administration in the US, the Federal Institute for Drugs and Medical Devices in Germany, the Medicines & Healthcare products Regulatory Agency in the UK as well as others, the National Library of Medicine, and elsewhere. Knowing which products or treatments are under advisory, which continue to be safe, what's new, and what fits a patient's situation requires substantial effort on the part of healthcare professionals and regulators alike. This paper outlines the current situation, describes some new approaches, and reports on a pilot test.
|
